- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
[作者:Dimopoulos, MA; Terpos, E; Chanan-Khan, A; Leung, N; Ludwig, H; Jagannath, S; Niesvizky, R; Giralt, S; Fermand, JP; Blade, J; Comenzo, RL; Sezer, O; Palumbo, A; Harousseau, JL; Richardson, PG; Barlogie, B; Anderson, KC; Sonneveld, P; Tosi, P; Cavo, M; Rajkumar, SV; Durie, BGM; San Miguel, J,期刊:Journal of clinical oncology, 页码:4976-4984 , 文章类型: Review,,卷期:2010年28-33]
- Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of ...
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
[作者:Von Hoff, DD; Stephenson, JJ; Rosen, P; Loesch, DM; Borad, MJ; Anthony, S; Jameson, G; Brown, S; Cantafio, N; Richards, DA; Fitch, TR; Wasserman, E; Fernandez, C; Green, S; Sutherland, W; Bittner, M; Alarcon, A; Mallery, D; Penny, R,期刊:Journal of clinical oncology, 页码:4877-4882 , 文章类型: Article,,卷期:2010年28-33]
- Purpose To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient's tumor with the PFS for the most recent regimen on which the patient had experienced pro...
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer
[作者:Sequist, LV; Gettinger, S; Senzer, NN; Martins, RG; Janne, PA; Lilenbaum, R; Gray, JE; Iafrate, AJ; Katayama, R; Hafeez, N; Sweeney, J; Walker, JR; Fritz, C; Ross, RW; Grayzel, D; Engelman, JA; Borger, DR; Paez, G; Natale, R,期刊:Journal of clinical oncology, 页码:4953-4960 , 文章类型: Article,,卷期:2010年28-33]
- Purpose IPI-504 is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90). Its potential anticancer activity has been validated in preclinical in vitro and in vivo models. We studied the activity of IP...
- Neuropathic Pain Features in Patients With Bone Metastases Referred for Palliative Radiotherapy
[作者:Kerba, M; Wu, JSY; Duan, QL; Hagen, NA; Bennett, MI,期刊:Journal of clinical oncology, 页码:4892-4897 , 文章类型: Proceedings Paper,,卷期:2010年28-33]
- Purpose To estimate the prevalence of pain with neuropathic features among patients with metastatic bone pain and to assess differences between patients with and without neuropathic features by pain severity, functional ...
- Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype
[作者:Morton, LM; Curtis, RE; Linet, MS; Bluhm, EC; Tucker, MA; Caporaso, N; Ries, LAG; Fraumeni, JF,期刊:Journal of clinical oncology, 页码:4935-4944 , 文章类型: Article,,卷期:2010年28-33]
- Purpose Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk o...
- Allogeneic Stem-Cell Transplantation in Patients With Waldenstrom Macroglobulinemia: Report From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
[作者:Kyriakou, C; Canals, C; Cornelissen, JJ; Socie, G; Willemze, R; Ifrah, N; Greinix, HT; Blaise, D; Deconinck, E; Ferrant, A; Schattenberg, A; Harousseau, JL; Sureda, A; Schmitz, N,期刊:Journal of clinical oncology, 页码:4926-4934 , 文章类型: Article,,卷期:2010年28-33]
- Purpose Allogeneic stem-cell transplantation (alloSCT) is a curative therapeutic option for patients with low-grade lymphoid malignancies. Information regarding alloSCT in Waldenstrom macroglobulinemia (WM) is limited. T...
- American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer
[作者:Rizzo, JD; Brouwers, M; Hurley, P; Seidenfeld, J; Arcasoy, MO; Spivak, JL; Bennett, CL; Bohlius, J; Evanchuk, D; Goode, MJ; Jakubowski, AA; Regan, DH; Somerfield, MR,期刊:Journal of clinical oncology, 页码:4996-5010 , 文章类型: Article,,卷期:2010年28-33]
- Purpose To update American Society of Clinical Oncology/American Society of Hematology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. Methods An Update Committee reviewed dat...
|